๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Treatment of advanced malignant hemangiopericytoma with combination adriamycin and dtic: A report of four cases

โœ Scribed by C. F. Beadle; B. L. Hillcoat


Publisher
John Wiley and Sons
Year
1983
Tongue
English
Weight
400 KB
Volume
22
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

โœฆ Synopsis


One patient with a large inoperable malignant hemangiopericytoma and three patients with local recurrence and/or metastases were treated with combination adriamycin, 50 mg/m2, and DTIC, 600-700 mg/m2, intravenously every 4 weeks. Two achieved palliation, one with measurable shrinkage of tumor, and the other with loss of incapacitating lower limb edema secondary to vascular and lymphatic obstruction. The third patient objectively had a less than partial response. The fourth patient did not respond to adriamycin and DTIC or to a subsequent trial of cis-platinum, 60 mg/m2, intravenously every 3 weeks. However, radiotherapy produced an objective response at the site of the local recurrence and relief of painful bone metastases. Two patients died of progressive disease; the third patient has stable disease and is continuing chemotherapy; and the fourth patient died, probably from adriamycin-induced cardiac failure in the presence of rapidly advancing intraabdominal metastases. The combination of adriamycin and DTIC is active in malignant hemangiopericytoma, and palliation of advanced disease can be achieved. However, prolonged survival is uncommon in the presence of a large tumor burden.


๐Ÿ“œ SIMILAR VOLUMES


Treatment of agnogenic myeloid metaplasi
โœ Lรฉvy, V.; Bourgarit, A.; Delmer, A.; Legrand, O.; Baudard, M.; Rio, B.; Zittoun, ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 235 KB ๐Ÿ‘ 2 views

Peripheral cytopenias are common in patients with agnogenic myeloid metaplasia (AMM). They are an important cause of morbidity and mortality, and their treatment is difficult. We report on 4 patients with AMM and severe cytopenia treated with danazol (400-600 mg/ day). Three of them became independe

Treatment of advanced ovarian cancer: A
โœ Bezwoda, W. R. ๐Ÿ“‚ Article ๐Ÿ“… 1986 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 395 KB

Fifty-one patients with ovarian cancer were tients with < 2 cm residual disease had sigentered in a randomised trial comparing treat-nificantly higher rate of complete remission rnent with cisplatin + adriamycin + cyclo-than those with > 2 crn residual disease. Carphosphamide (PAC) to cisplatin + 4'